Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-02; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting2024-08-20